drugset / Trial / NCT01509560
PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood
Phase 2
Completed
21 enrolled
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
ClinAssess · collabDeutsche Klinik fuer Diagnostik · collab
NaSingle-groupOpen-labelTreatment
Summary
In this prospective study is to examine whether the use of everolimus in patients after allogeneic SCT as part of GVHD prophylaxis for a further review in clinical studies is appropriate.
Timeline
- Start
- 2011-11-01
- Primary completion
- 2016-04-30
- Completion
- 2016-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 0.75 mg | — |